Pep19 may alter fat distribution without weight loss - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Pep19 may alter fat distribution without weight loss

  • By

  • Andrea Surnit

  • November 17, 2026

  • 5 min

Share

Objective:

To assess the effects of 90 days of oral Pep19 on regional fat distribution, metabolic measures, and safety in adults with obesity.

Approach:
  • Design and participants: Randomized, double-blind, placebo-controlled trial of 60 adults aged 21–60 years with obesity; 56 completed the study.
  • Intervention and outcomes: Participants received Pep19 5 mg, Pep19 10 mg, or placebo once daily. The primary endpoint was change in the DXA-measured android-to-gynoid fat ratio at day 90.
Key Findings:
  • Pep19 10 mg reduced the android-to-gynoid fat ratio versus placebo by an adjusted 3.58 percentage points; the 5-mg dose did not significantly affect the primary endpoint.
  • The 10-mg dose was associated with reduced abdominal and total skinfold thickness, but body weight, BMI, total fat mass, and lean mass did not differ significantly between groups.
  • HbA1c and HOMA-IR improved in Pep19 groups, while fasting glucose remained unchanged. These were secondary outcomes.
  • Lipid profiles, inflammatory biomarkers, and blood pressure showed no significant between-group differences.
  • No treatment-related toxicologic signals or clinically relevant laboratory abnormalities were identified during the 90-day study.
Interpretation:

The authors stated that the findings support improved metabolic regulation, but do not provide definitive proof of improved insulin sensitivity.

Limitations:
  • The sample was modest and follow-up was limited to 90 days.
  • The primary endpoint was significant as a percentage of baseline, but not in the supporting absolute-scale analysis.
  • HbA1c and HOMA-IR findings were secondary; baseline insulin resistance was higher in the 10-mg group.
  • Diet and physical activity were not objectively monitored, and target engagement or other mechanistic biomarkers were not assessed.
  • The exploratory responder analysis and recruitment from one geographic setting limit generalizability.
Conclusion:

Larger, longer-term trials are needed to assess whether the observed changes persist and translate into meaningful cardiometabolic benefits.

Sources:

Original Source(s)

Related Content